Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Biol Macromol ; 91: 905-10, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27208798

RESUMO

The weight-loaded swimming capability, tumor growth, survival time and biochemical markers of Ganoderma lucidum polysaccharides (GLPs) in a chemotherapy-related fatigue mouse model were tested in the present study. The results showed that the middle-dose GLPs (GLP-M) and the high-dose GLPs (GLP-H) could increase the exhausting swimming time, which was observed to decrease in the cisplatin control group(PCG) and the tumor control group (TCG).The GLP-M and the GLP-H had reduced serum levels of tumor necrosis factor-αand interleukin-6, which were up-regulated by cisplatin. Cisplatin and the presence of tumor significantly enhanced the malondialdehyde (MDA) content and inhibited the activity of superoxide dismutase (SOD) in the muscle. Administration of GLPs at a high dose decreased the levels of MDA and up-regulated the SOD activity. The high-dose GLPs+cisplatin group presented a decreased tendency of tumor volume and a lower tumor weight compared with PCG. Moreover, the mice in the GLP-M and GLP-H groups had longer survival times compared with the mice in the TCG and PCG.The levels of creatinine and serum blood urea nitrogen, which are up-regulated by cisplatin, were significantly reduced by GLP-M and GLP-H. Therefore, these results suggest that GLPs might improve chemotherapy-related fatigue via regulation of inflammatory responses, oxidative stress and reduction of nephrotoxicity.


Assuntos
Tratamento Farmacológico , Fadiga/induzido quimicamente , Fadiga/tratamento farmacológico , Polissacarídeos/uso terapêutico , Reishi/química , Células A549 , Animais , Nitrogênio da Ureia Sanguínea , Cisplatino/efeitos adversos , Creatinina/sangue , Fadiga/sangue , Interleucina-1beta/sangue , Interleucina-6/sangue , Masculino , Malondialdeído/metabolismo , Camundongos Endogâmicos BALB C , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/enzimologia , Superóxido Dismutase/metabolismo , Análise de Sobrevida , Natação , Fator de Crescimento Transformador alfa/sangue , Carga Tumoral/efeitos dos fármacos
2.
Int J Biol Macromol ; 50(1): 59-62, 2012 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-21983027

RESUMO

The anti-fatigue effects of the Radix Rehmanniae Preparata polysaccharides (RRPP) were studied in mice. The RRPP were orally administered at doses of 50, 100 and 200 mg/kg for 4 weeks and the anti-fatigue activity was evaluated using a weight-loaded swimming test, along with the determination of serum urea nitrogen (SUN), hepatic glycogen and blood lactic acid (BLA) contents. The results showed that there was no significant difference in the body weight of mice in the three RRPP groups compared with the negative control group during initial, intermediate and terminal stages in the experiment (p>0.05). The ratio of exhausting swimming time was obviously increased 31.48% (p<0.05) and 61.51% (p<0.01) in the middle-dose group and the high-dose RRPP group, respectively. The BLA and SUN levels were decreased in middle-dose and high-dose RRPP groups (p<0.01). Hepatic glycogen level was increased in three RRPP treated groups (p<0.01). Therefore, RRPP may be responsible for the pharmacological effect of anti-fatigue of Radix Rehmanniae Preparata. The mechanism was related to the increase of the storage of hepatic glycogen and the decrease of the accumulation of SUN and BLA.


Assuntos
Fadiga/tratamento farmacológico , Extratos Vegetais/farmacologia , Animais , Nitrogênio da Ureia Sanguínea , Peso Corporal , Relação Dose-Resposta a Droga , Ácido Láctico/sangue , Glicogênio Hepático/metabolismo , Substâncias Macromoleculares/química , Masculino , Medicina Tradicional Chinesa , Camundongos , Camundongos Endogâmicos BALB C , Polissacarídeos/química , Rehmannia , Natação , Fatores de Tempo
3.
Artigo em Inglês | MEDLINE | ID: mdl-23304226

RESUMO

Objectives. To assess the efficacy and safety of Liu Jun Zi Tang (LJZT) and Xiang Sha Liu Jun Zi Tang (XSLJZT) for treating functional dyspepsia. Methods. Literature searches were carried out on Medline database, Cochrane Library, CNKI database, Chinese Biomedical Literature database, Wanfang database, and VIP database up to July 2012. Hand search for further references was conducted. Study selection, data extraction, quality assessment, and data analyses were performed according to the Cochrane standards. Results. Fifteen publications in total were suitable for inclusion. There was evidence that LJZT compared with prokinetic drugs increased symptom improvement (odds ratio 1.96, 95% CI 1.15 to 3.36). There was also evidence that XSLJZT compared with prokinetic drugs increased symptom improvement (odds ratio 2.63, 95% CI 1.72 to 4.03). No adverse events were reported in LJZT or XSLJZT group in any of these randomized controlled trials. Conclusion. LJZT and XSLJZT might be more effective compared with prokinetic drugs in the treatment of functional dyspepsia, and no side effects are identified in the included trials. However, due to poor methodological quality in the majority of included studies, the potential benefit from LJZT and XSLJZT need to be confirmed in rigorously designed, multicentre, and large-scale trials.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...